IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.378
AS - Asia 2.797
EU - Europa 2.679
SA - Sud America 523
AF - Africa 490
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.878
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.205
SG - Singapore 1.497
RU - Federazione Russa 978
CN - Cina 683
IT - Italia 465
IE - Irlanda 441
BR - Brasile 417
CI - Costa d'Avorio 300
VN - Vietnam 257
UA - Ucraina 198
FR - Francia 156
CA - Canada 140
DE - Germania 105
KR - Corea 82
IN - India 80
GB - Regno Unito 75
NG - Nigeria 65
NL - Olanda 61
SN - Senegal 56
SE - Svezia 45
BD - Bangladesh 39
AR - Argentina 34
FI - Finlandia 29
PL - Polonia 29
ZA - Sudafrica 28
IQ - Iraq 24
MX - Messico 20
VE - Venezuela 20
CH - Svizzera 19
UZ - Uzbekistan 19
EC - Ecuador 16
TR - Turchia 15
HK - Hong Kong 14
PK - Pakistan 13
JP - Giappone 12
AT - Austria 11
CO - Colombia 11
ES - Italia 11
EG - Egitto 9
SA - Arabia Saudita 9
AU - Australia 8
LB - Libano 8
LT - Lituania 8
MA - Marocco 8
HR - Croazia 7
KE - Kenya 7
AZ - Azerbaigian 6
BE - Belgio 6
CL - Cile 6
PY - Paraguay 6
BJ - Benin 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
GR - Grecia 5
ID - Indonesia 5
JO - Giordania 5
NP - Nepal 5
PE - Perù 5
TN - Tunisia 5
BO - Bolivia 4
HU - Ungheria 4
IL - Israele 4
JM - Giamaica 4
RS - Serbia 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
IR - Iran 3
LK - Sri Lanka 3
PS - Palestinian Territory 3
RO - Romania 3
BA - Bosnia-Erzegovina 2
CG - Congo 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
MD - Moldavia 2
PA - Panama 2
PH - Filippine 2
BB - Barbados 1
BT - Bhutan 1
BY - Bielorussia 1
CR - Costa Rica 1
DM - Dominica 1
EU - Europa 1
GT - Guatemala 1
KG - Kirghizistan 1
KI - Kiribati 1
NI - Nicaragua 1
OM - Oman 1
PT - Portogallo 1
PW - Palau 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 11.878
Salva come PNG Salva come JPEG
Città #
Singapore 893
Dallas 849
Santa Clara 663
Chandler 562
Moscow 450
Dublin 438
Ashburn 323
San Jose 313
Abidjan 300
Chicago 204
Jacksonville 196
Boardman 176
Cambridge 119
Lawrence 119
Andover 116
Houston 116
Lauterbourg 112
Los Angeles 109
Nanjing 101
Beijing 94
Seoul 82
Toronto 82
Catania 79
Council Bluffs 77
Hefei 75
Ho Chi Minh City 70
Civitanova Marche 63
Des Moines 57
Dakar 56
Hanoi 53
Wilmington 49
Amsterdam 43
Nanchang 34
Grafing 33
Lagos 33
São Paulo 33
Shenyang 32
Bremen 31
New York 31
San Mateo 29
Ottawa 28
Saint Petersburg 28
Dong Ket 26
Abuja 25
Buffalo 25
The Dalles 23
Changsha 22
Hebei 22
Orem 22
Columbus 21
Lappeenranta 20
Jiaxing 19
San Francisco 19
Warsaw 19
Bari 18
Montreal 17
Tianjin 16
Washington 16
Chennai 15
Johannesburg 15
London 15
Denver 14
Mumbai 13
Phoenix 13
Da Nang 12
Rio de Janeiro 11
Seattle 11
Siracusa 11
Stockholm 11
Tokyo 11
Jinan 10
Poplar 10
Pune 10
Rome 10
Tashkent 10
Belo Horizonte 9
Elk Grove Village 9
Frankfurt am Main 9
Haiphong 9
Hong Kong 9
Naples 9
Norwalk 9
Padova 9
Zhengzhou 9
Baghdad 8
Brasília 8
Dhaka 8
Helsinki 8
Kunming 8
Ningbo 8
Palermo 8
Quito 8
Redondo Beach 8
Ann Arbor 7
Brooklyn 7
Den Haag 7
Guarulhos 7
Manchester 7
Messina 7
Porto Alegre 7
Totale 8.085
Salva come PNG Salva come JPEG
Nome #
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 201
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 181
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 172
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 168
Management of dysphagia in multiple sclerosis: current best practice 156
Comparison of genioglossus muscle activity and efficiency of dexmedetomidine or propofol during drug-induced sleep endoscopy in patients with obstructive sleep apnea/hypopnea syndrome 153
An update on the safety of treating relapsing-remitting multiple sclerosis 149
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 148
An update on the pharmacological management of pain in patients with multiple sclerosis 142
Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS 140
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 137
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 136
Association between dietary intake and function in amyotrophic lateral sclerosis 133
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset 131
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 130
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 129
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 129
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. 126
Can new chemical therapies improve the management of multiple sclerosis in children? 126
Approccio clinico e possibilità di trattamento nella SLA 126
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study 125
Post-Cerebrovascular Stroke and Early Dysphagia Assessment: A Systematic Review 123
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 123
CCSVI and MS. A population-based case-control study in Catania, Sicily. 123
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 123
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 123
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 114
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 113
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 113
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 113
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 112
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 112
Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis 111
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 110
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 110
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 110
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 109
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 108
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. 108
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 108
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 107
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 106
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 104
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 103
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 103
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 102
Primary cerebral vasculitis 102
Pharmacoeconomics of synthetic therapies for multiple sclerosis 102
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 102
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 101
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria 101
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 100
Wegener’s Granulomatosis Presenting as An Intracranial Hypertension Syndrome Treated with High Dose of Cyclophosphamide 100
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 100
Toxoplasma gondii and multiple sclerosis: a population-based case–control study 100
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 100
Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal 99
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 98
Palliative care in progressive multiple sclerosis 97
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 95
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 94
Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study 93
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 92
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 91
Detrimental effects of cyclophosphamide on seminal cells in men whith MS 90
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 86
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 86
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 85
Treatment options of cognitive impairment in multiple sclerosis 85
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 85
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 83
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 83
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 83
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 82
The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study 82
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 82
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 80
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 78
Multiple Sclerosis and CCSVI: A Population-Based Case Control Study 78
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 78
Gender related thyroid dysfunction and autoimmunità in multiple sclerosis patients treated with interferon-beta 77
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 77
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 76
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial 76
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 75
Cognitive-motor dual-task interference:A systematic review of neural correlates 74
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods 74
Genetic burden of common variants in progressive and bout-onset multiple sclerosis 74
The effects of different cognitive and motor tasks on the dual task cost of walking in multiple sclerosis: a case-control study 73
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 73
Negative prognostic impact of MRI spinal lesion in the early stages of relapsing-remitting multiple sclerosis 73
Prevalence of patient-reported disphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire) 72
Prevalence of pain in multiple sclerosis: a multicenter italian study 71
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 70
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 70
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question 70
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 69
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 67
Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Follewed by Interferon Beta Versus Interferon Beta. A Two-Year Randomized Trial 67
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 67
Totale 10.367
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202190 0 0 0 0 0 0 0 0 0 0 47 43
2021/2022799 79 130 15 8 125 4 123 22 52 5 41 195
2022/20231.609 128 84 30 164 154 282 4 281 386 6 68 22
2023/2024704 34 182 37 19 23 119 21 64 4 31 117 53
2024/20252.438 30 366 150 128 493 354 75 94 198 231 172 147
2025/20265.203 305 214 981 371 835 1.070 661 124 261 352 29 0
Totale 12.115